Biol Blood Marrow Transplant. 2010
Apr;16(4):548-54. Epub 2010 Jan 18.
Gain of 1q21 is an
unfavorable genetic prognostic factor for multiple
myeloma patients treated with high-dose
chemotherapy.
Nemec P, Zemanova Z, Greslikova H, Michalova K,
Filkova H, Tajtlova J, Kralova D, Kupska R,
Smetana J, Krejci M, Pour L, Zahradova L,
Sandecka V, Adam Z, Buchler T, Spicka I, Gregora
E, Kuglik P, Hajek R.
University Research Centre, Czech Myeloma Group,
Masaryk University, Kamenice 5,Brno, Czech
Republic. handcock@mail.muni.cz
Abstract
The prognostic significance of 1q21 gain,
del(13)(q14), del(17)(p13), t(4;14)(p16.3;q32),
and t(11;14)(q13;q32) detected by interphase
fluorescein in situ hybridization (FISH) was
studied in a cohort of 91 patients with newly
diagnosed multiple myeloma (MM). 1q21 gain was
detected in 37 of 91 patients (40.7%). In
comparison with patients lacking 1q21 gain,
patients with 1q21 gain had significantly
shorter progression-free survival (PFS) (14.9
versus 27.4 months; P = .044) and worse 4-year
overall survival (OS) (40.1% versus 76.2% of
patients; P = <.001). PFS or OS were not
influenced by the presence or absence of the
other studied chromosomal abnormalities.
Although the occurrence of 1q21 gain correlated
with deletion of 13q14, the presence of 1q21
gain can be considered an independent prognostic
factor, as no impact of del(13)(q14) as an
isolated chromosomal abnormality on either PFS
or OS has been observed. In comparison with
patients lacking 1q21 gain, patients with 1q21
gain were significantly more likely to
discontinue the preplanned treatment protocol
because of disease progression or death. We
conclude that 1q21 gain defines a prognostically
unfavorable group of MM patients.
Copyright (c) 2010 American Society for Blood
and Marrow Transplantation. Published by
Elsevier Inc. All rights reserved.
- PMID: 20005965 [PubMed - indexed for
MEDLINE]